Pharmacosmos and Simcere Pharmaceutical Group side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Pharmacosmos | Simcere Pharmaceutical Group |
|---|---|---|
| Phase 1 | 00% | Simcere Pharmaceutical Group: 9 of its 16 programs at phase 1
and 4 more — sign in to see them all |
| Phase 2 | 00% | Simcere Pharmaceutical Group: 1 of its 16 programs at phase 2
|
| Phase 3 | 00% | Simcere Pharmaceutical Group: 5 of its 16 programs at phase 3
|
| Approved, new studies | Pharmacosmos: 2 of its 2 programs at approved, new studies
| Simcere Pharmaceutical Group: 1 of its 16 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacosmos2 readouts · 2 phase 3 | · | · | · | · | · | Pharmacosmos, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | · | · | Pharmacosmos, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3
|
| Simcere Pharmaceutical Group2 readouts · 1 phase 3 | · | · | · | · | · | · | · | Simcere Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion
| Simcere Pharmaceutical Group, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · |
Changed in the last 90 days
Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Pharmacosmos
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 2
- trilaciclibapproved, new study · Oct 2027 → Feb 2028 (+3 mo) · moved Oct 5 · NCT05874401
- trilaciclibphase 3 · Jun 2027 → Oct 2027 (+5 mo) · moved Oct 2 · NCT07473128
Where they overlap
Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.
| Condition | Pharmacosmos | Simcere Pharmaceutical Group |
|---|---|---|
| Colorectal Neoplasmsboth · compare here | Pharmacosmos in Colorectal Neoplasms: 1 program
Their studies: Pharmacosmos’ studies of Colorectal Neoplasms in search | Simcere Pharmaceutical Group in Colorectal Neoplasms: 4 programs
Their studies: Simcere Pharmaceutical Group’s studies of Colorectal Neoplasms in search |
| Carcinoma, Non-Small-Cell Lungboth · compare here | Pharmacosmos in Carcinoma, Non-Small-Cell Lung: 1 program
Their studies: Pharmacosmos’ studies of Carcinoma, Non-Small-Cell Lung in search | Simcere Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 3 programs
Their studies: Simcere Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search |
| Carcinoma, Transitional Cellboth · compare here | Pharmacosmos in Carcinoma, Transitional Cell: 1 program
Their studies: Pharmacosmos’ studies of Carcinoma, Transitional Cell in search | Simcere Pharmaceutical Group in Carcinoma, Transitional Cell: 1 program
Their studies: Simcere Pharmaceutical Group’s studies of Carcinoma, Transitional Cell in search |
| Small Cell Lung Carcinomaboth · compare here | Pharmacosmos in Small Cell Lung Carcinoma: 1 program
Their studies: Pharmacosmos’ studies of Small Cell Lung Carcinoma in search | Simcere Pharmaceutical Group in Small Cell Lung Carcinoma: 1 program
Their studies: Simcere Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search |
| Triple Negative Breast Neoplasmsboth · compare here | Pharmacosmos in Triple Negative Breast Neoplasms: 1 program
Their studies: Pharmacosmos’ studies of Triple Negative Breast Neoplasms in search | Simcere Pharmaceutical Group in Triple Negative Breast Neoplasms: 1 program
Their studies: Simcere Pharmaceutical Group’s studies of Triple Negative Breast Neoplasms in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Pharmacosmos | Simcere Pharmaceutical Group |
|---|---|---|
| CDK4 | trilaciclibrule | trilaciclibrule |
| CDK6 | trilaciclibrule | trilaciclibrule |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.